Goldman adjusts Regeneron estimates following Q3 results

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

Goldman's Terence Flynn tweaks his Regeneron (REGN -3.6%) numbers a bit following Q3 results.

Flynn's new estimates: FY14 Eylea sales of $1.88B. That's down from $1.98B previously "to reflect single digit growth in H1 2014 (based on current trends) followed by an acceleration in H2 2014, which assumes Eylea receives priority review for DME."

New EPS targets for FY14/15/16: $9.89/$14.35/$16.19.

Buy rating maintained.

Price target cut to $353 from $355.